There are 2949 resources available
1085P - Health-related quality of life in stage III melanoma patients treated with neoadjuvant ipilimumab and nivolumab followed by index lymph node excision only versus therapeutic lymph node dissection: 24-week results of the PRADO trial
Presenter: Noelle Van Den Heuvel
Session: E-Poster Display
Resources:
Abstract
1086P - Cemiplimab for advanced cutaneous squamous cell carcinoma: Real life experience
Presenter: Candice Hober
Session: E-Poster Display
Resources:
Abstract
1087P - Time to clinically meaningful changes in pain in patients with advanced cutaneous squamous cell carcinoma treated with cemiplimab in a phase II clinical trial
Presenter: Michael R Migden
Session: E-Poster Display
Resources:
Abstract
1091P - Performance of Salamanca's refinement of the AJCC8 for T3 cutaneous squamous cell carcinoma (CSCC), versus the Brigham and Women's Hospital's alternative staging system and the Tübingen's alternative staging system for high-risk CSCC
Presenter: Laura Puebla-Tornero
Session: E-Poster Display
Resources:
Abstract
1093P - The features of the tumour microenvironment and the tumour budding identify prognostic subgroups in high-risk cutaneous squamous cell carcinoma
Presenter: Javier Cañueto
Session: E-Poster Display
Resources:
Abstract
1094P - Demographics, prior therapies and reasons for cemiplimab treatment: Prospective cemiplimAb-rwlc survivorship and epidemiology (C.A.S.E.) study in patients with advanced cutaneous squamous cell carcinoma (CSCC)
Presenter: Guilherme Rabinowits
Session: E-Poster Display
Resources:
Abstract
1095P - Exosomal microRNA in serum is a prognostic factor in cutaneous squamous cell carcinoma
Presenter: jong gwon choi
Session: E-Poster Display
Resources:
Abstract
1096P - Clinicopathologic risk factors for large cell transformation in patients with Sezary syndrome
Presenter: Redina Bardhi
Session: E-Poster Display
Resources:
Abstract
1097P - 4-year relapse-free survival (RFS), overall survival (OS) and long-term toxicity of (neo)adjuvant ipilimumab (IPI) + nivolumab (NIVO) in macroscopic stage III melanoma: OpACIN trial
Presenter: Judith Versluis
Session: E-Poster Display
Resources:
Abstract
1098P - Neoadjuvant cytoreductive treatment with BRAF/MEK inhibition of prior unresectable regionally advanced melanoma to allow complete surgical resection, REDUCTOR: A prospective single arm phase II trial
Presenter: Maartje Rohaan
Session: E-Poster Display
Resources:
Abstract